問卷

TPIDB > Search Result

Search Result

篩選

List

38Cases

2025-04-01 - 2027-12-31

Phase III

Active
A phase 3, two-part, randomized, open-label, modified trial comparing BMS-986365 with a trial-administered therapy (including Docetaxel or a second androgen receptor pathway inhibitor [ARPI]) in participants with metastatic castration-resistant prostate cancer (mCRPC) - rechARge
  • Condition/Disease

    Metastatic castration-resistant prostate cancer (mCRPC)

  • Test Drug

    BMS-986365 (CC-94676)

Participate Sites
4Sites

Recruiting4Sites

2024-10-01 - 2035-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2024-11-01 - 2031-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2029-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-12-30 - 2027-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-01-01 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-03-20 - 2030-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-26 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2018-10-30 - 2022-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-06-01 - 2027-11-06

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4